Placebo Controlled, Double Blind, Randomized Cardiovascular Outcome Study to Evaluate the Effect of 10 mg Obicetrapib in Participants With ASCVD Not Adequately Controlled Despite Maximally Tolerated Lipid Modifying Therapies
Placebo Controlled, Double Blind, Randomized Cardiovascular Outcome Study to Evaluate the Effect of 10 mg Obicetrapib in Participants With ASCVD Not Adequately Controlled Despite Maximally Tolerated Lipid Modifying Therapies
This study will be a placebo-controlled, double-blind, randomized, phase 3 study in participants with Atherosclerotic Cardiovascular Disease (ASCVD) who are not adequately controlled despite maximally tolerated lipid-lowering therapy.
This study will be a placebo-controlled, double-blind, randomized, phase 3 study to evaluate the effect of 10mg Obicetrapib in participants with Atherosclerotic Cardiovascular Disease (ASCVD) who are not adequately controlled despite maximally tolerated lipid-lowering therapy to reduce the risk of cardiovascular death, myocardial infarction, stroke and non-elective coronary revascularization. The PREVAIL Study
Inclusion Criteria:
Exclusion Criteria:
Torrance, California 90502, United States
Jacksonville, Florida 32204, United States
Jacksonville, Florida 32216, United States
Louisville, Kentucky 40213, United States
Haverhill, Massachusetts 01830, United States
North Massapequa, New York 11758-1802, United States
Asheboro, North Carolina 27203, United States
Charlotte, North Carolina 28204, United States
Greensboro, North Carolina 27401, United States
Pittsburgh, Pennsylvania 15236, United States
Rapid City, South Dakota 57701, United States
North Vancouver, British Columbia V7M 2H4, Canada
Sherbrooke, Quebec J1H 5N4, Canada
Hamburg, Germany
Jerusalem, 9112001, Israel
Gunma, 370-0829, Japan
Irbid, Jordan
Bydgoszcz, 85231, Poland
Gdynia, 81-157, Poland
Krakow, 31-202, Poland
Lodz, 93-338, Poland
Szczecin, 71-526, Poland
Warsaw, Poland
Wroclaw, 50-981, Poland